^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TP53 mutation + TSC2 mutation

    i
    Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1, TSC2, TSC Complex Subunit 2, Protein Phosphatase 1, Regulatory Subunit 160, Tuberous Sclerosis 2 Protein, Tuberin, TSC4, Tuberous Sclerosis 2, PPP1R160
    Entrez ID:
    7157; 7249
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Molecular Characterization of Malignant Renal Epithelioid Angiomyolipoma. (PubMed, Am J Clin Pathol)
    These findings highlight the molecular landscape of malignant renal EAML and expand on the existing literature suggesting a role for TP53 and ATRX alterations in malignant progression of these tumors. The presence of synchronous benign and malignant tumors within the same patient offers a unique opportunity to directly compare the molecular alterations, further supporting the association with aggressive behavior.
    Review • Journal
    |
    TP53 (Tumor protein P53) • ATRX (ATRX Chromatin Remodeler) • TSC2 (TSC complex subunit 2)
    |
    TP53 mutation • ATRX mutation • TSC2 mutation • TP53 mutation + TSC2 mutation